GFP
TEVA icon

Gryphon Financial Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Gryphon Financial Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-27,998
Closed -$684K – 180
2018
Q4 		$684K Buy
+27,998
New +$574K 0.17% 92
2018
Q3 		– Sell
-203
Closed -$5K – 748
2018
Q2 		$5K Buy
203
+58
+40% +$1.18K ﹤0.01% 681
2018
Q1 		$3K Sell
145
-400
-73% -$7.81K ﹤0.01% 807
2017
Q4 		$10K Buy
+545
New +$8.2K 0.01% 554

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gryphon Financial Partners's TEVA Position: Q1 2019 in Review

Gryphon Financial Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 27,998 shares — an estimated $684K sold.

Gryphon Financial Partners first reported a position in TEVA in Q4 2017 and held it in 4 quarters. The position peaked at $684K in Q4 2018. 521 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

  • Gryphon Financial Partners reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Gryphon Financial Partners sold 27,998 Teva Pharmaceuticals shares in Q1 2019, an estimated $684K.
  • Gryphon Financial Partners first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • Gryphon Financial Partners's Teva Pharmaceuticals position peaked at $684K in Q4 2018.
  • 521 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on Gryphon Financial Partners's 13F filing for Q1 2019, filed 7 May 2019.